Efficacy of Secukinumab in the treatment of moderate to severe psoriasis vulgarispatients - Secukinumab have a highefficacy in the treatment of moderate and severe psoriasis vulgaris, demonstrated by PASI score 23 decrease: Before treatment (22.35 ± 8.92), after 4 weeks (3.74 ± 2.71), after 8 weeks (0.71 ± 1.14), after 12 weeks (0.13 ± 0.3), after 16 weeks (0.08 ± 0.29) and after 24 weeks (0).